Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer), confirmed by a tissue sample taken within 6 months of joining the study
- People whose prostate cancer is classified as high risk or higher, based on the tumour having spread to nearby tissue, a high cancer grade (grade group 4 or 5), or a PSA level above 20 ng/mL
- People who have already started hormone therapy for high-risk prostate cancer, or who are planning to start it
- Adults aged 20 years or older
- People who are in good general physical condition, rated as ECOG 0 or 1 (meaning able to carry out normal daily activities with little or no restriction) (confirm with trial site)
- People who have given consent to a procedure involving a gel spacer called SpaceOAR, which is placed between the prostate and the rectum to reduce radiation exposure
Who may not be able to join:
- People who have had surgery to remove the prostate, or any prior surgery in the lower pelvic area, including surgery for rectal cancer
- People whose cancer has grown through the outer covering of the prostate at the back (posterior extracapsular extension) (confirm with trial site)
- People for whom the injection of a biodegradable substance is considered medically unsuitable, such as those with a tendency to bleed easily
- People who have previously had radiation therapy to the pelvic area
- People whose cancer has spread to the lymph nodes or to other parts of the body
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +82-2-3410-2616
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
NIH-NCI Common Terminology Criteria for Adverse Events (CTCAE) V 5.0 Frequency of rectal bleeding of grade 1 or higher within 3 years
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.